20.06
-0.04 (-0.20%)
| Previous Close | 20.10 |
| Open | 20.10 |
| Volume | 87,567 |
| Avg. Volume (3M) | 317,211 |
| Market Cap | 610,698,624 |
| Price / Sales | 2.24 |
| Price / Book | 0.610 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -13.94% |
| Operating Margin (TTM) | -26.95% |
| Diluted EPS (TTM) | -1.33 |
| Quarterly Revenue Growth (YOY) | 13.90% |
| Total Debt/Equity (MRQ) | 0.74% |
| Current Ratio (MRQ) | 6.32 |
| Operating Cash Flow (TTM) | 9.36 M |
| Levered Free Cash Flow (TTM) | -42.21 M |
| Return on Assets (TTM) | -3.69% |
| Return on Equity (TTM) | -3.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Fulgent Genetics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 33.42% |
| % Held by Institutions | 54.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (UBS, 49.55%) | Buy |
| Median | 25.50 (27.12%) | |
| Low | 21.00 (Piper Sandler, 4.69%) | Hold |
| Average | 25.50 (27.12%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 19.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 05 Aug 2025 | 30.00 (49.55%) | Buy | 20.78 |
| Piper Sandler | 04 Aug 2025 | 21.00 (4.69%) | Hold | 18.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Aug 2025 | Announcement | Fulgent Reports Second Quarter 2025 Financial Results |
| 17 Jul 2025 | Announcement | Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM |
| 10 Jul 2025 | Announcement | Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |